Nesiritide

Drug Profile

Nesiritide

Alternative Names: Brain natriuretic peptide - Scios; hBNP; JNS004; Natrecor; Noratak

Latest Information Update: 08 Jun 2015

Price : $50

At a glance

  • Originator Scios
  • Developer Cilag AG; Quintiles Transnational; Scios
  • Class Heart failure therapies; Natriuretic peptides; Nerve tissue proteins
  • Mechanism of Action Diuretics; Guanylate cyclase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • No development reported Cardiomyopathies; Heart failure
  • Discontinued Chronic heart failure; Postoperative hypertension

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Nov 2010 Efficacy and adverse events data from the phase III ASCEND-HF trial in Acute decompensated heart failure presented at the 83rd Annual Scientific Sessions of the American Heart Association
  • 30 Sep 2010 Scios completes enrolment in the phase III ASCEND-HF trial for Heart failure worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top